Drug Trial Radar · NCT01117441
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
Last checked: Nov 19, 2026Latest source record: May 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,136
Actual
Start
Jun 2010
Primary completion
Dec 31, 2021
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- University Hospital Schleswig-HolsteinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Deutsche Krebshilfe e.V., Bonn (Germany)
- First posted
- May 5, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rationale/Purpose: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia (ALL). This trial is studying several different combination chemotherapy regimens to compare how well they work in treating young patients with ALL. Study objectives Primary study questions: * Non high-risk (non-HR) precursor-B ALL (pB-ALL) patients with TEL/AML1-negative ALL or unknown TEL/AML1 status and flow cytometry minimal residual disease (MRD) in bone marrow on day 15 \<0.1% or with TEL/AML1-positive ALL (randomized study question R1): Can the daunorubicin dose in Protocol IA be safely reduced by 50 % with a non-inferior EFS and a reduction of toxicity (treatment-related mortality and AE/SAE in Protocol I)? * Patients with pB-ALL and risk group medium risk (MR) (randomized study question R2): Can the clinical outcome be improved by protracted asparagine depletion achieved through application of intensified PEG-L-asparaginase during reintensification and early maintenance? * High-risk (HR) patients (as identified by day 33 - randomized study question RHR): Can the clinical outcome be improved by protracted exposure to PEG-L-asparaginase during Protocol IB? Secondary study questions: * Standard risk (SR) patients identified by at least one sensitive marker: Is the clinical outcome comparable to that obtained in SR patients (identified with two sensitive markers) in AIEOP-BFM ALL 2000, or can the outcome even be improved with the use of PEG-L-asparaginase instead of native E. coli L-ASP? * T-ALL non-HR patients: Can the high level of outcome which was obtained for these patients in study AIEOP-BFM ALL 2000 be preserved or even improved with the use of PEG-L-ASP instead of native E. coli L-ASP? * HR patients with persisting high MRD levels despite the use of the HR blocks in the intensified consolidation phase "MRD Non-Responders": Is it possible to improve the outcome and to achieve a further reduction of leukemic cell burden by administration of an innovative treatment schedule (DNX-FLA)? * Patients participating in the randomized asparaginase studies (pB-ALL/MR, HR): Are asparaginase activity and asparaginase antibodies associated with development of allergic reactions, and do they have an effect on the outcome of the patients? * What is the relative value of different methods of MRD monitoring in the definition of alternative stratification systems within a BFM-oriented protocol?
Conditions
- Leukemia
Interventions
PEG-L-asparaginaseDrug
see detailed protocol description
cyclophosphamideDrug
see detailed protocol description
cytarabineDrug
see detailed protocol description
daunorubicin hydrochlorideDrug
see detailed protocol description
dexamethasoneDrug
see detailed protocol description
doxorubicin hydrochlorideDrug
see detailed protocol description
etoposideDrug
see detailed protocol description
ifosfamideDrug
see detailed protocol description
mercaptopurineDrug
see detailed protocol description
methotrexateDrug
see detailed protocol description
prednisoneDrug
see detailed protocol description
thioguanineDrug
see detailed protocol description
vincristine sulfateDrug
see detailed protocol description
vindesineDrug
see detailed protocol description
daunoxomeDrug
see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
fludarabineDrug
see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
Radiation TherapyRadiation
for eligibility for radiotherapy see detailed protocol description
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survivalTime frame: 10 years from the start of recruitment
- Disease-free survivalTime frame: 10 years from the start of recruitment
- minimal residual disease (MRD)Time frame: week 12 of treatment
Locations
139 sites in 7 countries. Site status is shown where the registry gives one.
The Sydney Children's Hospital, Centre for Children's Cancer and Blood Disorders
Randwick, Australia
The Children's Hospital at Westmead, Department of Oncology
Westmead, Australia
Krankenhaus Dornbirn, Abt. für Kinder- und Jugendheilkunde
Dornbirn, Austria
Univ.-Kinderklinik Graz, Abt. Pädiatrische Hämato-Onkologie
Graz, Austria
Department f. Kinder- u. Jugendheilkunde, Universitätsklinik f. Pädiatrie II
Innsbruck, Austria
A.oe. Landeskrankenhaus Klagenfurt, Abt. für Kinder- und Jugendheilkunde
Klagenfurt, Austria
A.oe. Landeskrankenhaus Leoben, Abt. für Kinder und Jugendliche
Leoben, Austria
Landes-Kinderklinik Linz, Haematologie/Onkologie
Linz, Austria
St. Johanns Spital / Landeskrankenhaus, Salzburg, Kinderspital Abt. Kinder u. Jugendheilkunde
Salzburg, Austria
St. Anna Kinderspital, Zentrum für Kinder- und Jugendheilkunde
Vienna, Austria
University Hospital Brno, Department of Pediatric Oncology
Brno, Czechia
Regional Hospital České Budějovice, Department of Pediatrics
České Budějovice, Czechia
University Hospital Hradec Králové, Department of Pediatrics
Hradec Králové, Czechia
University Hospital Olomouc, Department of Pediatrics
Olomouc, Czechia
Teaching Hospital Ostrava-Poruba, Department of Pediatrics
Ostrava-Poruba, Czechia
University Hospital Plzeň, Department of Pediatrics
Pilsen, Czechia
University Hospital Motol, Department of Pediatric Hematology and Oncology
Prague, Czechia
Masaryk´s Hospital Ústí nad Labem, Department of Pediatrics
Ústí nad Labem, Czechia
Kinderklinik der med. Fakultät der RWTH, Bereich Hämatologie/Onkologie
Aachen, Germany
I. Klinik für Kinder u. Jugendliche, Klinikum Augsburg, Hämatologie/ Onkologie
Augsburg, Germany
Klinikum Bayreuth, Kinderklinik
Bayreuth, Germany
Klinikum Berlin-Buch II. Kinderklinik, Bereich Onkologie/Allg. Pädiatrie
Berlin, Germany
Kinderklinik der Charité, Campus Virchow Klinikum (CVK), Abt.: Kinderhämatologie
Berlin, Germany
Städtisches Krankenhaus, Kinderklinik
Braunschweig, Germany
Klinikum Chemnitz gGmbH, Klinik für Kinder- und Jugendmedizin, Hämatologie / Onkologie
Chemnitz, Germany
Kliniken der Stadt Köln GmbH, Kinderkrankenhaus Riehl
Cologne, Germany
Med. Einrichtungen der Universität zu Köln, Klinik für Allg. Kinderheilkunde, Onkologisch-hämatologische Station
Cologne, Germany
Carl-Thiem-Klinikum, Kinderklinik, Abt. Hämatologie/Onkologie
Cottbus, Germany
Vestische Kinder- u. Jugendklinik, Universitätsklinik Witten/Herdecke
Datteln, Germany
Klinikum Lippe-Detmold, Kinder- und Jugendmedizin
Detmold, Germany
Klinikum Dortmund, Klinik f. Kinder- und Jugendmedizin
Dortmund, Germany
Uni.Klinik Carl Gustav Carus, Klinik f. Kinderheilkunde
Dresden, Germany
Universitätskinderklinik
Düsseldorf, Germany
Helios Klinikum Erfurt GmbH, Klinik für Kinderheilkunde
Erfurt, Germany
Universitätsklinikum Erlangen, Kinder- und Jugendmedizin, Abt. für Onkologie/ Hämatologie/Immunologie
Erlangen, Germany
Universitätsklinikum Essen, Kinderklinik, Hämatologie/Onkologie
Essen, Germany
Universitäts-Kinderklinik, Klinik für Kinderheilkunde III, Pädiatrische Hämatologie/Onkologie
Frankfurt, Germany
Universitäts-Kinderklinik, Haematologie/ Onkologie
Freiburg im Breisgau, Germany
Klinikum der Justus-Liebig-Universität, Zentrum für Kinderheilkunde, Abt. Hämatologie/Onkologie
Giessen, Germany
Universitäts-Kinderklinik Päd. I, Hämatologie/Onkologie
Göttingen, Germany
Showing 40 of 139 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.